Catheter ablation for atrial fibrillation on haemodialysis

Atrial fibrillation is common in end-stage kidney disease, especially among people receiving haemodialysis. In people with anaemia and volume overload, tachycardia can further impair ventricular filling and make breathlessness during or immediately after dialysis harder to manage. Atrial fibrillation catheter ablation for these patients can improve symptoms and ventricular function in selected cases, but the supporting evidence is less robust than for atrial fibrillation in the general population.

Randomised trials of pulmonary vein isolation generally excluded advanced kidney failure, so comparative effectiveness cannot be inferred from heart rhythm trials alone. Observational studies suggest that carefully selected dialysis recipients may have useful freedom from recurrent atrial tachyarrhythmia, yet younger age, less frailty, preserved left ventricular function and fewer comorbidities often drive those results. An episode that appears refractory is not automatically a reason to proceed.

Periprocedural anticoagulation adds a second layer of complexity. Kidney failure reduces drug clearance, while dialysis sessions use heparin and alter fluid, electrolyte and haemodynamic balance. Decisions should therefore connect electrophysiology, nephrology, procedural nursing and anticoagulation expertise rather than treating ablation as an isolated cardiology booking.

Why renal failure changes the rhythm decision

The rhythm-control question is partly a symptom question and partly a prognosis question. Persistent atrial fibrillation may reduce cardiac output during ultrafiltration, whereas recurrent rapid episodes can precipitate heart failure admissions. Ablation may be worthwhile when symptoms are substantial, drug therapy is ineffective or poorly tolerated, and the expected procedural burden is proportionate to the patient’s goals.

Australia’s renal service is dominated by public hospital programmes, with most people receiving thrice-weekly in-centre haemodialysis. Home haemodialysis exists, but availability and uptake vary markedly between states and territories. That variation matters for peri-ablation scheduling: a patient dialysing the morning after a morning ablation may need a different logistics plan from one who attends a late-afternoon unit.

Access to complex electrophysiology is concentrated in major centres such as Sydney, Melbourne, Brisbane, Perth and Adelaide. For people living in regional, rural or remote areas, including Darwin and northern Western Australia, travel and transfer can delay both ablation and post-procedure dialysis. Centres should avoid arranging a procedure without a confirmed place in the next haemodialysis schedule.

Patient priorities also vary. Frailty, cognition, symptom burden, anticipated changes to dialysis access, and possible renal transplantation all influence the balance. A patient seeking renal transplant may value durable rhythm control, but transplantation candidacy and timing must remain separate from the ablation decision.

Safety belongs in the procedural plan

Pulmonary vein isolation carries familiar procedural risks: vascular access injury, bleeding, cardiac tamponade, stroke, anaesthesia-related complications and contrast exposure. Residual urine output, volume status and recent haemodialysis must be documented beforehand. Contrast-sparing techniques, judicious imaging and an individualised fluid strategy are preferable to automatic hydration, which may worsen fluid overload.

Pre-procedural syncope deserves a specific cause. A structured syncope assessment helps distinguish orthostatic volume depletion and dialysis-related hypotension from an arrhythmic mechanism. The result can change pacing, imaging and ablation plans, and may identify a condition for which ablation would add risk without addressing the underlying problem.

Dialysis-specific haemostasis planning is equally important. Operators should review anticoagulant timing, recent heparin exposure, platelet count and haemoglobin trends, as well as the planned vascular access route. Femoral access may require extra care in some patients, while ultrasound-guided internal jugular access can be useful when appropriate. Previous heparin-induced thrombocytopenia changes the procedural anticoagulant strategy and must be identified before heparin is given.

Heparin dosing and any reversal strategy must be coordinated with the dialysis team. Heparin resistance, including reduced antithrombin activity, and the timing of the next haemodialysis can affect both the procedure and safe resumption of anticoagulation. These issues are best settled before admission, not after a complication.

Efficacy depends on selection and follow-up

Success after ablation in dialysis cohorts is generally reported in selected populations rather than unselected referrals. Freedom from atrial tachyarrhythmia can approach that seen in patients without kidney failure, especially in younger people with preserved ventricular function and limited atrial structural disease. The same cohorts also tend to show lower procedural complication rates, making direct comparison vulnerable to selection bias.

Longer follow-up often shows more recurrence, particularly with longstanding atrial fibrillation, atrial structural remodelling, obesity, heart failure or advancing frailty. Symptom improvement may nevertheless remain valuable even when continuous rhythm control is unrealistic. Shared decisions should therefore specify the intended benefit: fewer episodes, less medication, improved dialysis tolerance, fewer hospital admissions, or better exercise capacity.

Routine follow-up also differs across Australia. People in metropolitan services may return to the ablation centre for rhythm checks and device interrogation, while rural patients can rely on local cardiology, remote monitoring or transmission of ambulatory recordings. Whichever route is used, a reliable method is needed to detect recurrence and adjust rate or rhythm medication.

Anticoagulation should not be stopped merely because the procedure succeeded. Stroke prevention remains determined by thromboembolic risk, with renal function influencing drug choice and dose, and must be reviewed independently of apparent rhythm control.

Periprocedural anticoagulation needs a renal plan

Pulmonary vein ablation creates an environment in which thrombus formation can be consequential, so avoiding an unnecessary anticoagulant gap is a central safety objective. Warfarin is commonly used in haemodialysis, and a patient with a therapeutic international normalised ratio can often continue it through ablation; procedural unfractionated heparin is generally used during the intervention. Warfarin interruption is not automatically accompanied by heparin bridging: routine bridging increases bleeding exposure, and lower-molecular-weight heparin can accumulate in severe kidney failure.

For patients taking a direct oral anticoagulant, the last dose and restart time must follow the procedural protocol and the product information rather than a generic schedule. Apixaban and rivaroxaban have limited outcome data in haemodialysis, and renal clearance cannot be estimated reliably when residual function is negligible. Australian prescribing references, including Therapeutic Guidelines, help frame this uncertainty, but they do not replace specialist judgement. The journal’s special issue collections provide open-access starting points for updated reviews on arrhythmia management.

Routine anticoagulant level testing does not solve the problem. Anti-Xa concentrations are not validated for routine dose adjustment in haemodialysis, and an apparently therapeutic level does not establish protection from stroke. Clinical decisions should consider drug adherence, interactions, bleeding risk and dialysis timing, not simply a laboratory target.

The market context is relevant to access. Medicare covers public inpatient treatment, while elective ablation in a private hospital may involve Medicare Benefits Schedule rebates and private-insurer gaps; the Pharmaceutical Benefits Scheme (PBS) subsidises medicines rather than the procedure. PBS listing does not determine who benefits from ablation, and financial barriers can affect whether a patient reaches a high-volume centre.

After the procedure: dialysis and drug safety

The post-ablation plan should state when anticoagulation restarts, what happens if haemostasis is inadequate, and who receives that information. Many patients can resume their established anticoagulant once adequate haemostasis is confirmed, with timing adapted to the procedure and bleeding risk. Warfarin can generally be restarted without bridging, and routine short-term dual antiplatelet therapy adds bleeding without a separate indication.

Coordinate the restart with haemodialysis. Re-establishing systemic heparin too early or at a full conventional dose can be problematic after vascular puncture; the renal and nursing teams should specify the approach, monitor haemoglobin and inspect access sites. Watch for occult bleeding after the first post-procedure sessions, particularly when an anticoagulant and heparin exposure overlap.

A medication review should address renal accumulation, bleeding risk and interactions that are easy to miss: non-steroidal anti-inflammatory drugs, antiplatelet agents, some antibiotics and antifungals, and agents that alter anticoagulant exposure. Amiodarone or verapamil may be appropriate for rhythm control but can interact with anticoagulants and require monitoring. Dialysis patients also need clear advice about dehydration, constipation, infection and when to seek urgent care.

Culturally safe care is part of safe care. Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of chronic kidney disease and kidney failure, and transport, housing, food security and communication barriers can affect dialysis attendance and medication adherence. Involve Aboriginal health practitioners and local renal teams early, arrange practical support around appointments, and use an anticoagulation plan the patient can follow at home.

The Journal of Arrhythmia provides open-access articles and links to the Asia Pacific Heart Rhythm Society and Japanese Heart Rhythm Society; its journal information covers scope, readership and submission pathways.

Take a patient-centred approach: document symptoms, thromboembolic and bleeding risk, renal function, dialysis timing and access, then convene electrophysiology and nephrology before booking. Give the patient a written anticoagulation and dialysis schedule with a named contact for post-procedure concerns. Arrange that joint review before the next ablation booking and record the agreed plan in a single patient-facing document.